Globus Medical (NYSE: GMED) has recently received a number of price target changes and ratings updates:

  • 12/1/2017 – Globus Medical was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/20/2017 – Globus Medical was given a new $42.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 11/14/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at Gabelli.
  • 11/14/2017 – Globus Medical was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/10/2017 – Globus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 11/10/2017 – Globus Medical was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/10/2017 – Globus Medical was upgraded by analysts at Bank of America Corp from an “underperform” rating to a “neutral” rating.
  • 11/9/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $38.00 price target on the stock.
  • 11/9/2017 – Globus Medical had its price target raised by analysts at Barclays PLC from $27.00 to $29.00. They now have an “underweight” rating on the stock.
  • 11/9/2017 – Globus Medical had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 11/9/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $37.00 price target on the stock.
  • 10/19/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 10/19/2017 – Globus Medical had its price target lowered by analysts at Barclays PLC from $28.00 to $27.00. They now have an “underweight” rating on the stock.
  • 10/19/2017 – Globus Medical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/13/2017 – Globus Medical was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/7/2017 – Globus Medical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of Globus Medical, Inc. (GMED) opened at $37.62 on Monday. The company has a market cap of $3,625.67, a price-to-earnings ratio of 30.10, a price-to-earnings-growth ratio of 2.93 and a beta of 0.57. Globus Medical, Inc. has a 1 year low of $21.64 and a 1 year high of $38.85.

Globus Medical (NYSE:GMED) last issued its earnings results on Wednesday, November 8th. The medical device company reported $0.30 EPS for the quarter, hitting the consensus estimate of $0.30. The company had revenue of $151.74 million for the quarter, compared to analyst estimates of $150.73 million. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS. analysts forecast that Globus Medical, Inc. will post 1.27 EPS for the current year.

In other Globus Medical news, insider A Brett Murphy sold 15,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $29.99, for a total transaction of $449,850.00. Following the sale, the insider now directly owns 101,217 shares in the company, valued at approximately $3,035,497.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 28.21% of the stock is currently owned by insiders.

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Receive News & Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.